Stockholm3 is a blood test for early detection of aggressive prostate cancer. The test combines protein markers, genetic markers and clinical data in a proprietary algorithm for the purpose of detecting aggressive prostate cancer at an early stage. The result from Stockholm3 is a risk score that indicates the risk of aggressive prostate cancer and a recommendation that describes continued treatment.

When cancer is present in someone, it sheds tiny cells and tumour fragments into the bloodstream, called circulating tumour cells (CTCs). These cells are the main reason cancer eventually spreads in the body, especially if they move in clusters (a group). Trucheck can detect them from your blood sample and indicate the likely organ of origin. Tumour Healthcare professionals can then carry out targeted follow up investigations and treat patients if necessary.

A more precise test

Early detection is the key to successful treatment of prostate cancer. Today the blood test prostate-specific antigen (PSA) is used. One problem with PSA is that it misses between 30 and 50 percent of all aggressive cases of cancer. Research shows that Stockholm3 finds 100 percent more aggressive cases of cancer. This improves the ability to detect and treat cancer at an early stage.

Another problem with PSA is that it cannot distinguish between aggressive and benign cancer. Stockholm3 reduces the risk of conducting unnecessary prostate biopsies by 50 percent. As a result, many men do not have to undergo unnecessary follow-ups with a biopsy of the prostate, that can cause side effects such as sepsis as well as blood in the urine and feces.